In this issue:
Lyophilised oral FMT for UC
Induction etrolizumab in moderately to severely active UC
Induction and maintenance etrolizumab after anti-TNF for UC
CD exclusion diet for induction and maintenance of remission in mild–moderate CD
Worldwide postmarketing safety surveillance experience with tofacitinib for UC
COVID-19 outcomes in anti-TNF recipients
IBD prevalence in Greece
Serological response to COVID-19 mRNA vaccine in anti-TNF-treated IBD
Mirikizumab in CD
High-dose tofacitinib in acute severe UC after infliximab
Please login below to download this issue (PDF)